Fresenius Medical Care AG (NYSE:FMS – Get Free Report) has received an average rating of “Hold” from the five analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $22.00.
Several analysts recently weighed in on FMS shares. StockNews.com assumed coverage on Fresenius Medical Care in a research note on Wednesday, July 3rd. They issued a “strong-buy” rating on the stock. Truist Financial reduced their price target on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, July 31st.
Get Our Latest Stock Report on FMS
Institutional Investors Weigh In On Fresenius Medical Care
Fresenius Medical Care Trading Up 1.6 %
Shares of FMS opened at $18.98 on Monday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.14 and a current ratio of 1.46. Fresenius Medical Care has a 52-week low of $16.37 and a 52-week high of $24.70. The firm has a market cap of $11.14 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 1.01 and a beta of 0.90. The business’s fifty day moving average is $19.51 and its 200-day moving average is $19.93.
About Fresenius Medical Care
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
See Also
- Five stocks we like better than Fresenius Medical Care
- What is the Euro STOXX 50 Index?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- Are Penny Stocks a Good Fit for Your Portfolio?
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter.